Patent · US Active

Lentivirus packaging system, lentivirus produced by the same, cell transduced by the lentivirus, method for improving lentivirus production in a host cell, and method of using the cell for treating cancer

US11993782B2 · kind B2 · utility

0Cited by
1References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 16, 2021
Grant dateMay 28, 2024
Priority date
Expiry dateJul 16, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/16052
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided is a lentivirus packaging system, which comprises: a transfer plasmid comprising a nucleotide sequence of TAR-reserved-chimeric 5′ long terminal repeat (LTR); at least one packaging plasmid comprising a nucleotide sequence encoding TAR RNA binding protein, a nucleotide sequence of rev gene, a nucleotide sequence of gag gene, and a nucleotide sequence of pol gene; and an envelope plasmid. Due to the expression of gene of TAR RNA binding protein by the packaging plasmids, the produced lentivirus has higher virus titer and can improve the transduction rate and the gene delivery efficiency during cell transduction. The present invention further provides a method of improving lentivirus production in a host cell, which comprises using the lentivirus packaging system to transfect the host cell. The present invention further provides a cell transduced by the lentivirus and a method of using the cell for treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.